GlassScriptPhysician profile
Samridhi Narula Nallamshetty
NPI 1437274701
$8,563.17
in general payments reported to CMS, 2019-2025
31 companies · $2,047 in 2025
The $2,047 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $271 · 2021: $875 · 2022: $1,558 · 2023: $1,812 · 2024: $1,753 · 2025: $2,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,389 · Education: $197 · Consulting Fee: $25.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,389.38 |
| Education | $196.74 |
| Consulting Fee | $25.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,509.78 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $908.45 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Csl Behring | $840.61 | 2022-2025 | Hizentra, Haegarda, Andembry |
| Genzyme Corporation | $709.79 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $708.23 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $686.24 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $660.97 | 2020-2025 | Cuvitru, Hyqvia |
| Pfizer INC. | $324.57 | 2019-2025 | |
| Kaleo, INC. | $309.84 | 2019-2023 | Auvi-Q |
| Genentech USA, INC. | $299.40 | 2021-2025 | Xolair |
| Optinose US, INC. | $217.34 | 2019-2025 | |
| Amgen INC. | $212.32 | 2022-2025 | Tezspire, Actimmune |
| Pharming Healthcare, INC. | $185.27 | 2022-2025 | Ruconest |
| Blueprint Medicines Corporation | $173.22 | 2023-2025 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $99.51 | 2021-2025 | Orladeyo |
| Phadia US INC. | $76.94 | 2023-2024 | Immunocap |
| Leo Pharma INC. | $69.07 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $67.38 | 2025 | Neffy |
| Grifols USA, LLC | $64.57 | 2025 | Xembify |
| Teva Pharmaceuticals USA, INC. | $53.54 | 2021-2023 | |
| Insmed, INC. | $44.56 | 2025 | Brinsupri, Arikayce |
| Gc Biopharma USA, INC. | $38.45 | 2025 | Alyglo |
| Merck Sharp & Dohme LLC | $37.77 | 2021-2023 | |
| Ionis Pharmaceuticals, INC. | $32.24 | 2025 | Dawnzera |
| Covis Pharma Gmbh | $30.18 | 2023 | |
| Octapharma USA, INC. | $25.93 | 2021 | |
| Adma Biomanufacturing LLC | $25.44 | 2023 | |
| Shire North American Group INC | $23.55 | 2019 | |
| Hikma Pharmaceuticals USA | $16.14 | 2024 | Ryaltris |
| Mylan Pharmaceuticals INC. | $11.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samridhi Nallamshetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.